Buy & Sell Global X Robotics and Artificial Intelligence ETF (BOTZ) – Global X Robotics and Artificial Intelligence ETF Price Today
Aura AI Summary
Key Stats
- -Market Cap
- -Sector
- -12.95%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 73% Buy | 27% SellTrading Activity
- 86 daysTypical Hold Time
Over the past 52 weeks, Global X Robotics and Artificial Intelligence ETF has traded between a low of $30.45 and a high of $41.63, highlighting its annual price range. Over the past three months, Global X Robotics and Artificial Intelligence ETF has recorded a drawdown of -12.95%, reflecting recent price volatility. On average, investors hold Global X Robotics and Artificial Intelligence ETF for approximately 86 days, indicating typical investor behavior on the platform.
About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Most Recent News
Capital Link Shipping launches new CEO insights on tanker markets, maritime resilience, and capital markets.
Capital Link Shipping has expanded its Maritime Intelligence Hub with new executive insights from leaders at Scorpio Tankers, DHT Holdings, d’Amico International Shipping, and others. These discussions cover market trends in crude oil and product tan...

Centene offers voluntary staff buyouts amid major ACA membership drop
Centene, a major U.S. health insurer, has launched a voluntary separation program allowing eligible employees to apply for buyouts as it faces a significant decline in membership, especially in its Affordable Care Act (ACA) marketplace plans. Members...

US agency proposes broader Medicare coverage for heart valve device, boosting Edwards Lifesciences.
The US Centers for Medicare & Medicaid Services (CMS) proposed removing the coverage with evidence development (CED) requirement for Transcatheter Aortic Valve Replacement (TAVR) in patients with symptomatic severe aortic stenosis. CMS also suggested...
